Leukemia 2025 May
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Related Questions
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
1
2 Answers
Mednet Member
Medical Oncology · University of Washington
As implied by the question, there are now three (3) CD19 CAR-T cell products approved by the FDA for adults with relapsed/refractory B-ALL: tisagenlecleucel (tisa-cel), brexucabtagene autoleucel (brexu-cel), and obecabtagene autoleucel (obe-cel). They were all approved after single-arm prospective t...
What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?
3 Answers
Mednet Member
Pediatric Hematology/Oncology · Northwestern University Feinberg School of Medicine
Currently, there are no standard criteria used to choose CAR-T over conventional stem cell transplant as destination therapy. However, there are many factors that often push us in one direction or the other. As we learn more about outcomes after CAR-T cell therapy, there are many factors we know are...